Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | PRO1184 |
| Trade Name | |
| Synonyms | PRO-1184|PRO 1184|Rinatabart Sesutecan|Rina-S|GEN1184 |
| Drug Descriptions |
PRO1184 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FOLR1 linked to exatecan, which potentially inhibits growth of FOLR1-expressing tumors (Cancer Res 2022;82(12_Suppl):Abstract nr 1085). |
| DrugClasses | FOLR1-targeted Therapy 24 |
| CAS Registry Number | 2853518-95-1 |
| NCIT ID | C192818 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + PRO1184 | Bevacizumab PRO1184 | 0 | 1 |
| Carboplatin + PRO1184 | Carboplatin PRO1184 | 0 | 1 |
| Pembrolizumab + PRO1184 | PRO1184 Pembrolizumab | 0 | 1 |
| PRO1184 | PRO1184 | 0 | 2 |